In patients with established atherosclerotic cardiovascular disease, the addition of evolocumab to statin therapy reduces the risk of major adverse cardiovascular events by 20% compared to statin therapy alone.

Study: Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

The study tested adding evolocumab to statins in heart disease patients and found it reduced heart attacks, strokes, and heart-related deaths by 20%, just like the claim says.

Study: Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

The study tested whether adding a drug called evolocumab to statins helps prevent serious heart problems in people with heart disease. It found that it reduced the risk by 20%, just as the claim says.

Study: Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis

The study looked at whether adding evolocumab to statins helps prevent heart problems, and it found that it does—by about 15%, which is close to the claimed 20%.

Study: Efficacy of lipid lowering therapy beyond statins to prevent cardiovascular events

The study looked at adding drugs like evolocumab to statins and found they lower heart problem risks by about 19%, which is very close to the claimed 20% reduction.